# Eli Lilly and Company (LLY): Analyst Consensus Highlights 23.54% Potential Upside

- Link: https://www.directorstalkinterviews.com/eli-lilly-and-company-lly-analyst-consensus-highlights-23-54-potential-upside/4121244695
- Published: 2026-03-16T11:01:31+00:00
- Author: Madison Wilson

Eli Lilly and Company (NYSE: LLY), a stalwart in the healthcare sector, has been
attracting significant attention from investors, thanks to its robust market presence
and impressive growth metrics. With a market capitalization of $881.67 billion, 
Eli Lilly stands as a titan in the pharmaceutical industry, specializing in the 
development and marketing of human pharmaceuticals across the globe.

The company’s current stock price hovers around $985.08, barely changing with a 
modest 0.01% uptick. This price is within a 52-week range of $625.65 to $1,109.94,
indicating substantial volatility and an equally substantial opportunity for investors
eyeing potential entry points.

Key valuation metrics offer a mixed picture. While the trailing P/E ratio is currently
unavailable, the forward P/E stands at 23.48, aligning with industry standards and
suggesting investor optimism regarding future earnings. The absence of a PEG ratio,
along with other standard valuation metrics, could suggest a focus on growth rather
than current earnings performance.

Eli Lilly’s performance metrics are nothing short of impressive, with a staggering
42.60% revenue growth, which underscores the company’s ability to scale its operations
effectively. The EPS of 22.95 and a remarkable return on equity of 101.16% highlight
the company’s efficiency in generating profit from shareholders’ investments. Additionally,
a free cash flow of approximately $1.95 billion provides ample liquidity for future
investments and shareholder returns.

Despite a modest dividend yield of 0.63%, the payout ratio of 26.14% indicates a
conservative approach to dividend distribution, allowing for reinvestment in growth
opportunities. This approach aligns with the company’s strategic focus on long-term
value creation.

Analyst ratings further bolster the investment case for Eli Lilly. With 24 buy ratings,
6 hold ratings, and only 1 sell rating, the consensus portrays a strong bullish 
sentiment. The average target price of $1,216.93 suggests a potential upside of 
23.54%, a compelling figure for investors seeking growth opportunities. The target
price range spans from $870.00 to $1,500.00, reflecting diverse analyst perspectives
on the company’s future performance.

Technical indicators offer additional insights into the stock’s trajectory. The 
current RSI of 29.95 indicates that the stock may be oversold, potentially signaling
a buying opportunity. However, the MACD of -14.39 and Signal Line of -11.82 suggest
bearish momentum, warranting cautious optimism and careful monitoring of market 
trends.

Eli Lilly’s diverse product portfolio, which includes treatments for cardiometabolic
health, oncology, immunology, and more, ensures a steady stream of revenue and growth
opportunities. Strategic collaborations with notable entities like Boehringer Ingelheim
Pharmaceuticals and F. Hoffmann-La Roche Ltd further enhance its R&D capabilities
and market reach.

Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly’s longstanding
history and consistent innovation continue to drive its market leadership. For investors,
Eli Lilly presents a balanced proposition of growth potential and stable returns,
making it a noteworthy consideration in the ever-evolving healthcare sector.

Share on:
